CD274 and non-small cell lung carcinoma: Furthermore, the standard biomarker for ICI therapy, PD-L1 TPS, has less straightforward utility in EGFRm tumors and biomarkers to predict ICI response are not yet standardized in EGFRm NSCLC patients.